Back to results
US 2025/0084098 A1Published application
Fused-ring amine derivative
AssigneesSumitomo Pharma Co., Ltd., Carna Biosciences, Inc.
InventorsShingo TOJO, Daisuke URABE, Hitoshi WATANABE
Life of this patent
Estimating the term…
Abstract
The present invention provides a fused-ring amine derivative that has a DYRK inhibitory effect and that is represented by formula (1) (refer to the description with respect to A1, L1, T, Z and l in the formula), or a pharmaceutically acceptable salt thereof.
Claims20
A compound represented by:
- wherein
- A1 represents optionally substituted methylene or an oxygen atom,
- L1 represents optionally substituted methylene or optionally substituted ethylene,
- 1 represents 1, 2, or 3,
- T represents a hydrogen atom or optionally substituted C1-6 alkyl,
- Z represents —NR1R2 or —OR3,
- R1 and R2 each independently represent a hydrogen atom, optionally substituted C1-6 alkyl, or
- C(O)—RA, or R1 and R2, together with the nitrogen atom to which they are attached, may form an optionally substituted 4- to 7-membered saturated heterocycle,
- RA represents —RA1 or —ORA1,
- RA1 represents optionally substituted C1-6 alkyl,
- R3 represents a hydrogen atom, optionally substituted C1-6 alkyl, or C(O)—RB, and
- RB represents optionally substituted C1-6 alkyl,
- or a pharmaceutically acceptable salt thereof.
10 more elements
Dependencies are inferred from the claim text.